A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
Authors
Keywords
Economic Evaluation, Zoledronic Acid, Medication Adherence, Teriparatide, Denosumab
Journal
PHARMACOECONOMICS
Volume 33, Issue 3, Pages 205-224
Publisher
Springer Nature
Online
2014-11-15
DOI
10.1007/s40273-014-0231-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
- (2014) Matt D. Stevenson et al. PHARMACOECONOMICS
- Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
- (2014) Mickaël Hiligsmann et al. ARTHRITIS RESEARCH & THERAPY
- Health Technology Assessment in Osteoporosis
- (2013) Mickael Hiligsmann et al. CALCIFIED TISSUE INTERNATIONAL
- Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
- (2013) K. Kim et al. OSTEOPOROSIS INTERNATIONAL
- A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures
- (2013) L. Si et al. OSTEOPOROSIS INTERNATIONAL
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. PHARMACOECONOMICS
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
- Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
- (2013) Mickaël Hiligsmann et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Osteoporosis in the European Union: medical management, epidemiology and economic burden
- (2013) E. Hernlund et al. Archives of Osteoporosis
- Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
- (2013) Anju Parthan et al. Applied Health Economics and Health Policy
- The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
- (2012) Daniel R Murphy et al. BMC MUSCULOSKELETAL DISORDERS
- Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision
- (2012) Kazem Alzahouri et al. JOINT BONE SPINE
- Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
- (2012) Mickael Hiligsmann et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan
- (2012) Kensuke Moriwaki et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
- (2012) O. Ström et al. OSTEOPOROSIS INTERNATIONAL
- Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland
- (2012) K. Lippuner et al. OSTEOPOROSIS INTERNATIONAL
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- (2012) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- A systematic review of hip fracture incidence and probability of fracture worldwide
- (2012) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis
- (2012) Mickaël Hiligsmann et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada
- (2012) D. Chau et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy
- (2011) Annalise N. Pham et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Partial adherence: a new perspective on health economic assessment in osteoporosis
- (2011) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium
- (2011) Mickaël Hiligsmann et al. PHARMACOECONOMICS
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- ISPOR States Its Position on Network Meta-Analysis
- (2011) A.E. Ades VALUE IN HEALTH
- A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence
- (2011) Susan Ross et al. VALUE IN HEALTH
- The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands
- (2011) R. Akehurst et al. JOURNAL OF MEDICAL ECONOMICS
- Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
- (2010) Mickaël Hiligsmann et al. BONE
- Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer
- (2010) M. Ivergård et al. BONE
- FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example
- (2010) O. Ström et al. BONE
- Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications
- (2010) Mickaël Hiligsmann et al. CALCIFIED TISSUE INTERNATIONAL
- Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis
- (2010) Patrice Fardellone et al. JOINT BONE SPINE
- Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
- (2010) J.-J. Body et al. OSTEOPOROSIS INTERNATIONAL
- Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
- (2010) F. Borgström et al. OSTEOPOROSIS INTERNATIONAL
- Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
- (2010) B. Jönsson et al. OSTEOPOROSIS INTERNATIONAL
- Does the Funding Source Influence the Results in Economic Evaluations?
- (2010) Rachael L. Fleurence et al. PHARMACOECONOMICS
- Cost–effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
- (2010) Mickaël Hiligsmann et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective
- (2010) Jean-Blaise Wasserfallen et al. JOURNAL OF MEDICAL ECONOMICS
- Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis
- (2010) Fredrik Borgström et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years
- (2009) Mickaël Hiligsmann et al. BONE
- Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age
- (2009) Ego Seeman et al. BONE
- Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
- (2009) Véronique Rabenda et al. EXPERT OPINION ON PHARMACOTHERAPY
- Cost-Effectiveness of Hormone Therapy in the United States
- (2009) Ingrid Lekander et al. JOURNAL OF WOMENS HEALTH
- The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
- (2009) F. Borgström et al. OSTEOPOROSIS INTERNATIONAL
- The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®
- (2009) F. Borgström et al. OSTEOPOROSIS INTERNATIONAL
- Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women
- (2009) M. Hiligsmann et al. OSTEOPOROSIS INTERNATIONAL
- Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis
- (2009) Mickaël Hiligsmann et al. VALUE IN HEALTH
- The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis
- (2009) Melissa Thompson et al. VALUE IN HEALTH
- The Cost-effectiveness of Hormone Therapy in Younger and Older Postmenopausal Women
- (2008) Shelley R. Salpeter et al. AMERICAN JOURNAL OF MEDICINE
- Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands
- (2008) Jeroen P. Jansen et al. CURRENT MEDICAL RESEARCH AND OPINION
- FRAX™ and the assessment of fracture probability in men and women from the UK
- (2008) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK
- (2008) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK—Results based on the Women's Health Initiative randomised controlled trial
- (2007) Ingrid Lekander et al. BONE
- The cost-effectiveness of alendronate in the management of osteoporosis
- (2007) John A. Kanis et al. BONE
- The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
- (2007) Hansheng Ding et al. JOURNAL OF BONE AND MINERAL METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started